Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
5101
-
5102
Time course analysis of DYRK1A and DYRK1B KD in HBV-infected dHepaRG cells.
Published 2024Subjects: -
5103
Chemical inhibitors targeting DYRK1A and DYRK1B reduce HBV RNAs production.
Published 2024Subjects: -
5104
-
5105
-
5106
-
5107
-
5108
-
5109
-
5110
<b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b>
Published 2025“…<p dir="ltr">This post hoc analysis assessed sustainability of lowered HbA1c and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk. …”
-
5111
Correlations between volumetric decrease in rACC and average cortisol levels for patients (A) and controls (B) and correlations between volumetric decrease in rACC and the combined CTQ scales for physical and sexual abuse for patients (C) and controls (D).
Published 2013“…<p>Correlations between volumetric decrease in rACC and average cortisol levels for patients (A) and controls (B) and correlations between volumetric decrease in rACC and the combined CTQ scales for physical and sexual abuse for patients (C) and controls (D).…”
-
5112
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
5113
-
5114
-
5115
-
5116
Loss of the Hypoxia Induced Transcriptional Regulator SrbB Results in a Significant Growth Defect and Red Pigmented Mycelia in Hypoxia.
Published 2014“…<p>(A). Growth of Δ<i>srbB</i> in normoxia and hypoxia on solid media. …”
-
5117
Polymorphisms in <i>CYP1B1</i>, <i>CYP3A5</i>, <i>GSTT1</i>, and <i>SULT1A1</i> Are Associated with Early Age Acute Leukemia
Published 2015“…<i>CYP1B1</i> polymorphism was associated with a decreased risk of AML either for non-white or female children (additive model: OR = 0.24; 95% CI: 0.08–0.76, <i>p</i> < 0.01; additive model: aOR = 0.27; 95% CI: 0.08–0.89, <i>p</i> = 0.03, respectively). …”
-
5118
Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study
Published 2019“…<p><b>Background</b>: Gait disorders are common in Parkinson’s disease patients who respond poorly to dopaminergic treatment. Blockade of adenosine A<sub>2A</sub> receptors is expected to improve gait disorders. …”
-
5119
Effects of Hypoxia Exposure on Hepatic Cytochrome P450 1A (CYP1A) Expression in Atlantic Croaker: Molecular Mechanisms of CYP1A Down-Regulation
Published 2012“…Hypoxia exposure (dissolved oxygen, DO: 1.7 mg/L for 2 to 4 weeks) caused significant decreases in hepatic CYP1A mRNA and protein levels compared to CYP1A levels in fish held in normoxic conditions. …”
-
5120